Product Description
Mechanisms of Action: ADRA2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Juvantia Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Multiple System Atrophy|Shy-Drager Syndrome|Parkinson's Disease|Hypotension, Orthostatic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01149811 |
Fipamezole | N/A |
Completed |
Parkinson's Disease |
2010-11-01 |
2019-05-14 |
Treatments |
|
NCT01140841 |
Fipamezole | N/A |
Completed |
Parkinson's Disease |
2010-11-01 |
2019-05-14 |
||
NCT00758849 |
Foehn | P2 |
Unknown status |
Shy-Drager Syndrome|Parkinson's Disease|Hypotension, Orthostatic|Multiple System Atrophy |
2009-05-01 |
2019-03-18 |
Treatments |
|
NCT00559871 |
Fjord | P2 |
Completed |
Parkinson's Disease |
2009-05-01 |
2019-03-22 |
Treatments |
|
2007-004890-24 |
FOEHN | P2 |
Active, not recruiting |
Multiple System Atrophy|Parkinson's Disease|Hypotension, Orthostatic |
2009-01-07 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|